Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Pauci-immune glomerulonephritis (GN) with antineutrophil cytoplasmic antibodies (ANCA) is a form of rapidly progressive GN comprising about 90% of pauci-immune glomerulonephritis, and associated with the presence of circulating ANCA (mostly directed against proteinase-3 (PR3) and myeloperoxidase (MPO)). Patients usually present with hematuria and rapidly declining renal function, often leading to dialysis within weeks without treatment. Cutaneous, pulmonary, musculoskeletal and nervous involvement may be observed in case of systemic disease, and the correlation between ANCA titer and disease activity has been demonstrated.
Biomarker and diagnostic research for pauci-immune glomerulonephritis with ANCA has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for pauci-immune glomerulonephritis with ANCA.
109 publications have been identified in PubMed for pauci-immune glomerulonephritis with ANCA. Research spans Case Report / Case Series (66%), Review / Meta-Analysis (16%), and Epidemiology / Natural History (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 72 | 66% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 12:27 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries
17 |
16% |
Disease patterns and progression | 12 | 11% |
Testing and diagnosis research | 4 | 4% |
Laboratory research | 2 | 2% |
Other research | 1 | 1% |
Clinical study results | 1 | 1% |
Mohanraj K (2026). [PMID: 42051845](https://pubmed.ncbi.nlm.nih.gov/42051845/). *Cureus*. [Case Report / Case Series]
Yıldırım S (2026). [PMID: 41719207](https://pubmed.ncbi.nlm.nih.gov/41719207/). *Nephron*. [Diagnostic / Biomarker]
Yamane T (2026). [PMID: 41326926](https://pubmed.ncbi.nlm.nih.gov/41326926/). *Clin Rheumatol*. [Review / Meta-Analysis]
Parmar MS (2026). [PMID: 28613478](https://pubmed.ncbi.nlm.nih.gov/28613478/). *Unknown Journal*. [Case Report / Case Series]
Almaani S (2026). [PMID: 42025332](https://pubmed.ncbi.nlm.nih.gov/42025332/). *Am J Kidney Dis*. [Review / Meta-Analysis]
Kumru G (2026). [PMID: 41654351](https://pubmed.ncbi.nlm.nih.gov/41654351/). *Nefrologia (Engl Ed)*. [Review / Meta-Analysis]
Berrocal C (2026). [PMID: 41976855](https://pubmed.ncbi.nlm.nih.gov/41976855/). *J Clin Med*. [Case Report / Case Series]
Sunaga A (2026). [PMID: 42139079](https://pubmed.ncbi.nlm.nih.gov/42139079/). *Mod Rheumatol Case Rep*. [Case Report / Case Series]
Rodelo-Ceballos J (2026). [PMID: 41537456](https://pubmed.ncbi.nlm.nih.gov/41537456/). *J Clin Rheumatol*. [Epidemiology / Natural History]
Kutsarova S (2026). [PMID: 41562823](https://pubmed.ncbi.nlm.nih.gov/41562823/). *Reports (MDPI)*. [Case Report / Case Series]
AI-curated news mentioning pauci-immune glomerulonephritis with ANCA
Updated Jan 21, 2026
A recent study explores pauci-immune endocapillary proliferative glomerulonephritis, highlighting the role of glomerular M2 macrophage infiltration. This research contributes to understanding the disease's pathology and potential therapeutic targets.